74 results about "Ocular implant" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering an implant to treat an ocular disorder is disclosed. The ocular implant can include a treatment fluid that is released over the course of several days or months to treat an ocular disorder. A system for implanting and retrieving spent implants can include an implant, an external housing, and an implant assembly. The external housing can provide access to a sliding trigger. The sliding trigger can convert a portion of the implant assembly from a first configuration to a second configuration and a second configuration to a third configuration to release or retrieve an implant. In some embodiments, the implant assembly can include a collet formed from sheet metal and bent to act as a spring. The collet can have protrusions to match the profile of an implant to secure the implant during delivery. Actuation of the trigger can relieve the spring's pressure.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto- retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

This invention discloses an ocular implant and its delivery system, comprising: a flexible substrate; multiple nanowire arrays disposed on the flexible substrate; an elastic ring disposed along the circumferential edge of the flexible substrate, the elastic ring having elastic memory and capable of returning to its original shape before deformation after deformation; and two opposing openings disposed near the edge of the flexible substrate. The nanowire array of the ocular implant of this invention can be composed of multiple materials spliced ​​together, and materials with different efficacies and photosensitive wavelengths can be selected for splicing. Therefore, personalized ocular implants can be customized according to different patient conditions to achieve a better match with the patient's fundus condition. Furthermore, the folding and opening design of the ocular implant of this invention, as well as the self-expanding property of the elastic ring, enable it to be adapted to a delivery system for positioning and minimally invasive implantation.

DRUG ELUTING OCULAR IMPLANT

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

An insertion device for an ocular implant for regulating intraocular pressure includes a cannula having an internal space for receiving at least a portion of an ocular implant having a stent and an implant opening for inserting the ocular implant; a handle configured to be connected to the cannula and held by a surgeon; and a holder configured to be coupled to the handle and including a receiving portion configured to receive the stent of the ocular implant. The ocular implant insertion device appropriately fixes the stent inserted into the tube of the ocular implant in a manner attached to the insertion device, thereby preventing problems such as the stent coming out of the tube, the implant being separated from the insertion device by the stent, or the stent obscuring the surgeon's field of vision during implant implantation surgery.

The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

The invention relates to an extra-ocular implant (1) used to prevent worsening of pathological myopia, the implant comprising a support structure (10) produced in the form of an arm having, at a first end, anchoring means and a second end comprising a concavity (120), the implant (1) being characterized in that it further comprises a pouch (13) in which a compound suitable for inflating the pouch (13) is arranged, the pouch (13) being positioned at the second end of the arm so as to occupy the concavity (120), the implant (1) further comprising an attachment device (130) arranged on the pouch (13) for positioning against the posterior portion of the eye.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

The disclosure relates to novel methods and materials particularly useful for ophthalmic applications and to methods for making and using the same. More particularly, the disclosure relates to relatively soft, optically transparent, foldable, high refractive index materials particularly suited for use in the production of intraocular lenses, contact lenses, and other ocular implants and to methods for manufacturing and implanting IOLs made therefrom.

The present invention relates to a method for the production of an ocular implant, wherein dexamethasone — commonly employed in the treatment of macular edema resulting from retinal vein occlusion (RVO) and diabetic macular edema (DME) — is encapsulated within a nanofibrous matrix fabricated via electrospinning, and said nanofibers are subsequently coated onto a contact lens surface.

The present invention relates to an ocular implant for the controlled release of a therapeutic agent or drug, comprising: a) at least 0.1% w / w of a therapeutic agent; b) 5% to 95% w / w of a cross-linked polymer matrix; c) and 0.1% to 40% w / w of a biodegradable polymer wherein the cross-linked polymer matrix is obtained by cross-linking a photopolymerizable composition, characterized in that the outer surface of the ocular implant is at least partially coated with at least one coating layer. The invention also relates to a method of manufacturing the above ocular implant.

Disclosed are ocular implants, ocular implant delivery systems, and methods of deploying an ocular implant. For example, the ocular implant can comprise a plurality of supporting frames and spines connecting the supporting frames. The ocular implant can comprise a distal supporting frame configured as an open trough having a trough nadir at a distal end. The trough nadir can be positioned radially outward of the spines. The ocular implant can also comprise a proximal portion comprising a pair of tool engagement ears curled laterally inward toward one another. A delivery system used to deploy the ocular implant can comprise a cannula comprising a distal portion having a proximal curved bend and a distal curved bend. The proximal curved bend can be bent in a different direction than the distal curved bend. The delivery system can also comprise a camera coupled to the cannula.

1. The name of this design product: Guide portion of an eye incision guide tool. 2. Purpose of the product of this design: The product of this design is used to guide the creation of an incision in the eye, such as for implanting an ocular implant (e.g., a drug delivery device). The part requiring protection is the guide portion of the eye incision guide tool. 3. The key point of the design of this product lies in the shape of the product. 4. The picture or photo that best illustrates the key points of the design: Design 1 Stereoscopic Drawing 1. 5. Designate Design 1 as the base design. 6. Other circumstances that require explanation: The parts indicated by dotted lines in each design are not the subject of the request for protection. The dotted lines in Design 2, Design 3, Design 5 and Design 6 are the dividing lines between the areas requiring protection and the areas not requiring protection, and are not inherent lines on the products.

Described herein are devices configured to enable efficient grasping and delivery of film implants at open or minimally invasive surgical sites. An exemplary device includes: a tip portion configured to secure and protect a membrane implant device during treatment and installation to a surgical site; a handle portion configured to control the vacuum source; and a shaft portion configured to control vacuum and deliver vacuum from the vacuum source to the tip portion.

An ocular implant adapted to be disposed within Schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant.

The present invention relates to an ocular implant comprising an amorphous solid dispersion (ASD) comprising a tyrosine kinase inhibitor (TKI), such as axitinib, and a polymer excipient. Further, the invention relates to methods of treatment using the ocular implant of the invention comprising the amorphous solid dispersion (ASD) in treating an ocular disease. According to the present invention, ocular diseases are treated by injecting an amorphous solid dispersion (ASD) or an ocular implant comprising the ASD into the eye, wherein the ocular implant releases the TKI. Moreover, the invention relates to processes for preparing an amorphous solid dispersion (ASD) and an ocular implant of the invention comprising an ASD.

The present disclosure relates to intraocular drug-eluting particulate implants and dry particulate formulations comprising a plurality of drug-eluting particulate implants for use in the treatment of conditions of the eye, wherein the implants are configured to deliver a drug to the eye without a carrier. The present disclosure also relates to methods of treating conditions of the eye by delivering one or more drugs from a drug eluting implant or dry particulate formulation to the anterior chamber, posterior chamber (e.g., ciliary sulcus), iris corneal horn, sclera, cornea, limbus, subconjunctival space, subcapsular space, and vitreous body.